A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis

Nutrition

Volumn 25, Issue 5, 2009, Pages 520-525

  Fujimori, Shunji ^a   Gudis, Katya ^a   Mitsui, Keigo ^a   Seo, Tsuguhiko ^a   Yonezawa, Masaoki ^a   Tanaka, Shu ^a   Tatsuguchi, Atsushi ^a   Sakamoto, Choitsu ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Inflammatory bowel disease questionnaire; Prebiotics; Probiotics; Synbiotics; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; BIFICOLON; C REACTIVE PROTEIN; ISAGOL; ISPAGULA; PREDNISOLONE; PROBIOTIC AGENT; SYNBIOTIC AGENT; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BIFIDOBACTERIUM LONGUM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EMOTION; FEMALE; HUMAN; INTESTINE FUNCTION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SOCIAL STATUS; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADULT; BIFIDOBACTERIUM; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; DRUG SYNERGISM; FEMALE; HUMANS; MALE; PROBIOTICS; PSYLLIUM; QUALITY OF LIFE; TREATMENT OUTCOME;

BIFIDOBACTERIUM LONGUM;

EID: 63049108842     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nut.2008.11.017     Document Type: Article

References (39)

1. Duchmann R., Kaiser I., Hermann E., Mayet W., Ewe K., and Meyer zum Büschenfelde K.H. Tolerance exists towards resident intestinal flora but is broken in active inflammatory disease (IBD). Clin Exp Immunol 102 (1995) 448-455
2. Schultsz C., Van Den Berg F.M., Ten Kate F.W., Tytgat G.N., and Dankert J. The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology 117 (1999) 1089-1097
3. Campieri M., and Gionchetti P. Bacteria as the cause of ulcerative colitis. Gut 48 (2001) 132-135
4. Sadlack B., Merz H., and Schorle H. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75 (1993) 253-261
5. Taurog J.D., Richardson J.A., Croft J.T., Simmons W.A., Zhou M., Fernández-Sueiro J.L., et al. The germ free state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 180 (1994) 2359-2364
6. Hartley M.G., Hudson M.J., Swarbrick E.T., Hill M.J., Gent A.E., Hellier M.D., et al. The rectal mucosa associated microflora in patients with ulcerative colitis. J Med Microbiol 36 (1992) 96-103
7. Matsuda H., Fujiyama Y., Andoh A., Ushijima T., Kajinami T., and Bamba T. Characterization of antibody responses against rectal mucosa-associated bacterial flora in patients with ulcerative colitis. J Gastroenterol Hepatol 15 (2000) 61-68
8. Macfarlane S., furrie E., Cummings J.H., and Macfarlane G.T. Chemotaxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis. Clin Infect Dis 38 (2004) 1690-1699
9. Sartor R.B. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126 (2004) 1620-1633
10. Kruis W., Schutz E., Fric P., Fixa B., Judmaier G., and Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 11 (1997) 853-858
11. Rembacken B.J., Snelling A.M., Hawkey P.M., Chalmers D.M., and Axon A.T. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354 (1999) 635-639
12. Venturi A., Gionchetti P., Rizzello F., Johansson R., Zucconi E., Brigidi P., et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 13 (1999) 1103-1108
13. Ishikawa H., Akedo I., Umesaki Y., Tanaka R., Imaoka A., and Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 22 (2003) 56-63
14. Kruis W., Fric P., Pokrotnieks J., Lukas M., Fixa B., Kascak M., et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53 (2004) 1617-1623
15. Gionchetti P., Rizzello F., Venturi A., Brigidi P., Matteuzzi D., Bazzocchi G., et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119 (2000) 305-309
16. Gionchetti P., Rizzello F., Helwig U., Venturi A., Lammers K.M., Brigidi P., et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind placebo controlled trial. Gastroenterology 124 (2003) 1202-1209
17. Furrie E., Macfarlane S., Kennedy A., Cummings J.H., Walsh S.V., O'Neil D.A., et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 54 (2005) 242-249
18. Fujimori S., Tatsuguchi A., Gudis K., Kishida T., Mitsui K., Ehara A., et al. High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease. J Gastroenterol Hepatol 22 (2007) 1199-1204
19. Guyatt G., Mitchell A., Irvine E.J., Singer J., Williams N., Goodacre R., et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 96 (1989) 804-810
20. Hashimoto H., Green J., Iwao Y., Sakurai T., Hibi T., and Fukuhara S. Reliability, validity, and responsiveness of the Japanese version of the Inflammatory Bowel Disease Questionnaire. J Gastroenterol 38 (2003) 1138-1143
21. Watanabe K., Funayama Y., Fukushima K., Shibata C., Takahashi K., Ogawa H., et al. Assessment of the Japanese inflammatory bowel disease questionnaire in patients after ileal pouch anal anastomosis for ulcerative colitis. J Gastroenterol 41 (2006) 662-667
22. Tumbull G.K., and Vallis T.M. Quality of life in inflammatory bowel disease: the interaction of disease activity with psychosocial function. Am J Gastroenterol 90 (1995) 1450-1454
23. Madsen S.M., Schlichting P., Davidsen B., Nielsen O.H., Federspiel B., Riis P., et al. An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. Am J Gastroenterol 96 (2001) 1807-1815
24. Hauser W., Dietz N., Steder-Neukamm U., Janke K.H., and Stallmach A. Biopsychosocial determinants of health-related quality of life after ileal pouch anal anastomosis for ulcerative colitis. Inflamm Bowel Dis 10 (2004) 399-407
25. Zahn A., Hinz U., Karner M., Ehehalt R., and Stremmel W. Health-related quality of life correlates with clinical and endoscopic activity indexes but not with demographic features in patients with ulcerative colitis. Inflamm Bowel Dis 12 (2006) 1058-1067
26. Alcala M.J., Casellas F., Fontanet G., Prieto L., and Malagelada J.R. Shortened questionnaire on quality of life for inflammatory bowel disease. Inflamm Bowel Dis 10 (2004) 383-389
27. Trevisi P., De Filippi S., Minieri L., Mazzoni M., Modesto M., Biavati B., et al. Effect of fructo-oligosaccharides and different doses of Bifidobacterium animalis in a weaning diet on bacterial translocation and Toll-like receptor gene expression in pigs. Nutrition 24 (2008) 1023-1029
28. Moorthy G., Murali M.R., and Devaraj S.N. Lactbacilli facilitate maintenance of intestinal membrane integrity during Shigella dysenteriae 1 infection in rats. Nutrition 25 (2009) 350-358
29. Fujiwara M., Kaneko T., Iwana H., Taketomo N., Tsunoo H., Kanno J., et al. Inhibitory effects of Bifidobacterium longum on experimental ulcerative colitis induced in mice by synthetic dextran sulfate sodium. Digestion 67 (2003) 90-95
30. Bai A.P., Ouyang Q., Xiao X.R., and Li S.F. Probiotics modulate inflammatory cytokine selection from inflamed mucosa in active ulcerative colitis. Int J Clin Pract 60 (2006) 284-288
31. Takahashi N., Kitazawa H., Iwabuchi N., Xiao J.Z., Miyaji K., Iwatsuki K., et al. Oral administration of an immunostimulatory DNA sequence from Bifidobacterium longum improves Th1/Th2 balance in a murine model. Biosci Biotechnol Biochem 70 (2006) 2013-2017
32. Sameshima Y., Sameshima T., Hirakawa A., Niwa K., Nagata Y., Sameshima K., et al. Effects of chitosan oral hard capsules containing Bifidobacterium longum on ulcerative colitis. J Anal Biosci 28 (2005) 420-427
33. Hallert C., Kaldma M., and Petersson B.G. Ispaghula husk may relieve gastrointestinal symptoms in ulcerative colitis in remission. Scand J Gastroenterol 26 (1991) 747-750
34. Fernandez-Banares F., Hinojosa J., Sanchez-Lombrana J.L., Navarro E., Martínez-Salmerón J.F., García-Pugés A., et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol 94 (1999) 427-433
35. Rath H.C., Herfarth H.H., Ikeda J.S., Grenther W.B., Hamm Jr. T.E., Balish E., et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest 98 (1996) 945-953
36. Mortensen P.B., and Clausen M.R. Short-chain fatty acids in the human colon: relation to gastrointestinal health and disease. Scand J Gastroenterol 31 (1996) 132-148
37. Wenzl H.H., Fine K.D., Schiller L.R., and Fordtran J.S. Determinants of decreased fecal consistency in patients with diarrhea. Gastroenterology 108 (1995) 1729-1738
38. Eherer A.J., Santa Ana C.A., Porter J., and Fordtran J.S. Effect of psyllium, calcium polycarbophil, and wheat bran on secretory diarrhea induced by phenolphthalein. Gastroenterology 104 (1993) 1007-1012
39. Bliss D.Z., Jung H.J., Savik K., Lowry A., LeMoine M., Jensen L., et al. Supplementation with dietary fiber improves fecal incontinence. Nurs Res 50 (2001) 203-213